![](https://ml-eu.globenewswire.com/media/84159208-c519-49a5-86c6-56151e3ab92b/small/ena-png.png)
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral ...
MELBOURNE, Australia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US …